Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:54 PM
Ignite Modification Date:
2025-12-24 @ 4:54 PM
NCT ID:
NCT00377650
Eligibility Criteria:
Inclusion Criteria:
* ST elevation acute myocardial infarction within 6 hours since pain onset, with 2 mm ST segment elevation in two lead
* Minimum 3 mm ST segment elevation in one leads
* Vessel reference diameter \> 2.5 mm
* When vessel reference diameter ≥ 4,0 mm than additional distal protection device (filter) is needed during stent implantation
Exclusion Criteria:
* Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA, thienopirydins or GP IIb/IIIa inhibitors
* Active bleeding or coagutopathy
* Prior CABG or PCI
* Known ejection fraction EF \<35%
* Cardiogenic shock /SBP \< 90 mmHg, IABP and/or catheloamins usage/
* LBBB, pacemaker rhythm
* Severe calcifications
* Previous Myocardial infarction
* Stroke history
* Patient directly after reanimation
* Known thrombocytopenia- platelets \< 100 000
* Pregnancy
* Cancer disease
* No future patient cooperation expected
* Patient's taking part in the other clinical trials
* Fibrynolisis directly administered before PCI
* Renal insufficiency (creatynine \> 220 µmol/ml), hemodialysis
* Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA, thienopirydins or GP IIb/IIIa inhibitors
* Active bleeding or coagutopathy
* Prior CABG or PCI
* Known ejection fraction EF \<35%
* Cardiogenic shock /SBP \< 90 mmHg, IABP and/or catheloamins usage/
* LBBB, pacemaker rhythm
* Severe calcifications
* Previous Myocardial infarction
* Stroke history
* Patient directly after reanimation
* Known thrombocytopenia- platelets \< 100 000
* Pregnancy
* Cancer disease
* No future patient cooperation expected
* Patient's taking part in the other clinical trials
* Fibrynolisis directly administered before PCI
* Renal insufficiency (creatynine \> 220 µmol/ml), hemodialysis
* Liver insufficiency
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00377650
Study Brief:
Protocol Section:
NCT00377650